Cas no 122111-03-9 (Gemcitabine hydrochloride)

Gemcitabine hydrochloride is a nucleoside analog antimetabolite used primarily as an antineoplastic agent. Its chemical structure, 2'-deoxy-2',2'-difluorocytidine monohydrochloride, enables incorporation into DNA, leading to chain termination and inhibition of DNA synthesis. This compound is particularly effective in treating various cancers, including pancreatic, non-small cell lung, and ovarian cancers, due to its selective cytotoxicity toward rapidly dividing cells. Gemcitabine hydrochloride exhibits high solubility in aqueous solutions, facilitating intravenous administration. Its prodrug activation via intracellular phosphorylation enhances therapeutic efficacy while minimizing systemic toxicity. The hydrochloride salt form ensures stability and consistent pharmacokinetic properties, making it a reliable choice for clinical applications.
Gemcitabine hydrochloride structure
Gemcitabine hydrochloride structure
Product Name:Gemcitabine hydrochloride
CAS No:122111-03-9
MF:C9H12ClF2N3O4
MW:299.659088134766
MDL:MFCD01735988
CID:63582
PubChem ID:125307627
Update Time:2025-08-25

Gemcitabine hydrochloride Chemical and Physical Properties

Names and Identifiers

    • Gemcitabine Hydrochloride
    • 2',2'-Difluoro-2'-deoxycytidine
    • 2,2-Difluoro-2-deoxycytidineDDFC
    • 2',2'-Difluorodeoxycytidine
    • 2'-Deoxy-2',2'-difluorocytidine
    • 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidin-2-one hydrochloride
    • Gemcitabine
    • Gemcitabine HCl
    • dFdCyd
    • 2'-DEOXY-2',2'-DIFLUORO-CYTIDIN MONOHYDROCHLORIDE
    • Gemcitabine, Hydrochloride Salt (dFdC, dFdCyd,LY-188011, NSC 613327, Gemzar?,Gamcitabine?,Gemcitera?, Gemsar?,Zefei?)
    • LY 188011 hydrochloride
    • 2',2'-Difluoro-2'-deoxycytidine hydrochloride
    • dFdC Gemzar (Lilly) LY-188011 dFdC dFdCyd
    • Gemcitabine HCl(TABINES)
    • Gemzar (Lilly)
    • LY-188011
    • dFdC
    • DDFC
    • gemzar
    • GeMsar
    • ly188011
    • GeMcitera
    • Gecitabine
    • 2′-Deoxy-2′,2′-difluorocytidine
    • 2′-Deoxy-2′,2′-difluorocytidine; dFdC
    • 2'-Deoxy-2',2'-difluorocytidine monohydrochloride
    • LY188011 hydrochloride
    • Gemcitabine (Hydrochloride)
    • Gemcitabine HCL (Gemzar)
    • C9H11F2N3O4.HCl
    • Cytidine, 2'-deoxy-2',2'-difluoro-, monohydrochloride
    • U347PV74IL
    • 2',2'-Difluorodeoxycytidine monohydrochloride
    • DSSTox_RID_82590
    • DSSTox_CID_27827
    • DSSTox_GSID_47849
    • 2'-deoxy-2',2'-difluorocytidine hydrochloride
    • 2'-Deoxy-2',2'-d
    • 2'-D
    • 122111-03-9 (HCl)
    • Gemcitabine hydrochloride (JAN/USP)
    • 4-AMINO-1-((2R,4R,5R)-3,3-DIFLUORO-4-HYDROXY-5-(HYDROXYMETHYL)OXOLAN-2-YL)PYRIMIDIN-2-ONE HYDROCHLORIDE
    • Gemzar (TN)
    • BG164501
    • LY-188011 . HCl
    • GEMCITABINE HYDROCHLORIDE [EP MONOGRAPH]
    • NCGC00168784-03
    • 2'Deoxy-2',2'-Difluorocytidine, Hydrochloride
    • NSC613327
    • GEMCITABINE HYDROCHLORIDE [USP MONOGRAPH]
    • Tox21_112644_1
    • 2'-deoxy-2',2'-difluorocytidine, hydrochloride
    • HY-B0003
    • 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one hydrochloride
    • EX-A837
    • MLS003915643
    • (2'R,4'R,5'R)-4-Amino-1-(3,3-difluoro-4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyridin-2-one hydrochloride
    • GEMCITABINE HYDROCHLORIDE [USP-RS]
    • 2'-DEOXY-2',2'-DIFLUOROCYTIDINE MONOHYDROCHLORIDE (.BETA.-ISOMER)
    • W-60402
    • 2'-Deoxy-2',2'-difluorocytidine monohydrochloride (beta-isomer)
    • Gemcitabine hydrochloride (USAN:USP)
    • DTXSID3047849
    • Gemcitabine hydrochloride, United States Pharmacopeia (USP) Reference Standard
    • LY-188011 HYDROCHLORIDE
    • GEMCITABINE HYDROCHLORIDE (USP-RS)
    • GEMCITABINE HYDROCHLORIDE (USP MONOGRAPH)
    • AS-13656
    • Q27114559
    • NCGC00168784-01
    • GEMCITABINE HYDROCHLORIDE [ORANGE BOOK]
    • FF-10832
    • FF 10832
    • Gemcitabine hydrochloride [USAN]
    • GEMCITABINE HYDROCHLORIDE [WHO-DD]
    • CAS-122111-03-9
    • D01155
    • 1-(2-Oxo-4-amino-1,2-dihydropyrimidin-1-yl)-2-deoxy-2,2-difluororibose, hydrochloride
    • 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-onehydrochloride
    • SMR000469146
    • EN300-7361886
    • SCHEMBL4366
    • INFUGEM
    • LY 188011
    • CCG-267459
    • GEMCITABINE HYDROCHLORIDE [MI]
    • Gemcitabine hydrochloride, European Pharmacopoeia (EP) Reference Standard
    • GEMCITABINE HYDROCHLORIDE [JAN]
    • 122111-03-9
    • 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one hydrochloride
    • CHEBI:31647
    • J-700175
    • BDBM50247964
    • 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydrochloride
    • Gemcitabine hydrochloride, >=98% (HPLC)
    • 2'-Deoxy-2',2'-difluorocytidine HCL
    • CS-0755
    • GEMCITABINE HYDROCHLORIDE (MART.)
    • Gemcitabine HCI
    • s1149
    • CHEMBL1637
    • FF10832
    • Gemcitabine (as hydrochloride)
    • AKOS015999730
    • DTXCID3027827
    • GEMCITABINE HYDROCHLORIDE (EP MONOGRAPH)
    • GEMCITABINE HYDROCHLORIDE [VANDF]
    • Gemcitabine hydrochloride,(S)
    • UNII-U347PV74IL
    • Gemcitabine hydrochloride [USAN:USP]
    • GEMCITABINE HYDROCHLORIDE [MART.]
    • MFCD01735988
    • Tox21_112644
    • Gemcitabine HCl (Gemzar,LY188011)
    • Gemcitabine Hydrochloride,Gemzar, LY-188011
    • Inno-D07001
    • Gemcitabine HCl , Gemzar , LY188011 , LY 188011 hydrochloride
    • Gemcitabine HCl (Gemzar,LY188011)?
    • Gemcitabine hydrochloride
    • MDL： MFCD01735988
    • Inchi： 1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1
    • InChI Key： OKKDEIYWILRZIA-OSZBKLCCSA-N
    • SMILES： Cl.FC1([C@H](N2C(N=C(C=C2)N)=O)O[C@H](CO)[C@H]1O)F

Computed Properties

  • Exact Mass: 299.04800
  • Monoisotopic Mass: 263.071762
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 4
  • Hydrogen Bond Acceptor Count: 6
  • Heavy Atom Count: 19
  • Rotatable Bond Count: 2
  • Complexity: 426
  • Covalently-Bonded Unit Count: 2
  • Defined Atom Stereocenter Count: 3
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 108
  • Surface Charge: 0
  • Tautomer Count: 3
  • XLogP3: _1.5

Experimental Properties

  • Color/Form: White to Yellow Solid
  • Density: ==
  • Melting Point: 292°C(lit.)
  • Boiling Point: No data available
  • Flash Point: 245.7℃
  • Refractive Index: 268
  • Solubility: H2O: ≥10mg/mL
  • PSA: 110.60000
  • LogP: 0.09460
  • λmax: 268(H2O)(lit.)
  • Merck: 4386
  • Specific Rotation: +43 °- +50° (c=1, water)
  • Solubility: Not determined
  • Vapor Pressure: No data available

Gemcitabine hydrochloride Security Information

  • Symbol: GHS08
  • Prompt：warning
  • Signal Word：Danger
  • Hazard Statement： H360
  • Warning Statement： P201,P308+P313
  • Hazardous Material transportation number：NONH for all modes of transport
  • WGK Germany：3
  • Hazard Category Code： 21-36/38-46-62-63
  • Safety Instruction： S25; S26; S36/37; S53
  • RTECS：HA3840000
  • Hazardous Material Identification： Xn
  • Safety Term：25-26-36/37-53
  • Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month
  • Risk Phrases：R21

Gemcitabine hydrochloride Customs Data

  • HS CODE：2934999090
  • Customs Data：

    China Customs Code:

    2934999090

    Overview:

    2934999090. Other heterocyclic compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

    Declaration elements:

    Product Name, component content, use to

    Summary:

    2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Gemcitabine hydrochloride Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
MedChemExpress
HY-B0003-10mM*1mLinDMSO
Gemcitabine hydrochloride
 122111-03-9 99.89%
10mM*1mLinDMSO
 ￥792 2023-07-26
MedChemExpress
HY-B0003-100mg
Gemcitabine hydrochloride
 122111-03-9 99.89%
100mg
 ￥720 2025-04-15
MedChemExpress
HY-B0003-200mg
Gemcitabine hydrochloride
 122111-03-9 99.89%
200mg
 ￥1080 2025-04-15
MedChemExpress
HY-B0003-500mg
Gemcitabine hydrochloride
 122111-03-9 99.89%
500mg
 ￥1980 2025-04-15
MedChemExpress
HY-B0003-1g
Gemcitabine hydrochloride
 122111-03-9 99.89%
1g
 ￥3100 2025-04-15
AstaTech
45018-1/G
GEMCITABINE HCL
 122111-03-9 97%
1g
 $39 2023-09-17
AstaTech
45018-5/G
GEMCITABINE HCL
 122111-03-9 97%
5g
 $117 2023-09-17
AstaTech
45018-25/G
GEMCITABINE HCL
 122111-03-9 97%
25g
 $350 2023-09-17
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI
YG2527-100mg
Gemcitabine hydrochloride
 122111-03-9 ≥98%
100mg
 ￥1900元 2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI
YG2527-25mg
Gemcitabine hydrochloride
 122111-03-9 ≥98%
25mg
 ￥650元 2023-09-15

Gemcitabine hydrochloride Production Method

Gemcitabine hydrochloride Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:122111-03-9)鹽酸吉西他賓
Order Number:LE6073532
Stock Status:in Stock
Quantity:25KG,200KG,1000KG
Purity:99%
Pricing Information Last Updated:Friday, 20 June 2025 12:46
Price ($):discuss personally
Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:122111-03-9)Gemcitabine hydrochloride
Order Number:sfd16072
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:37
Price ($):discuss personally
NewCan Biotech Limited
Gold Member
Audited Supplier Audited Supplier
(CAS:122111-03-9)Gemcitabine hydrochloride
Order Number:NC8917
Stock Status:
Quantity:10g
Purity:97%
Pricing Information Last Updated:Friday, 18 July 2025 16:17
Price ($):Price inquiry

Gemcitabine hydrochloride Spectrogram

1H NMR 300 MHz DMSO
1H NMR
13C NMR
13C NMR

Gemcitabine hydrochloride Related Literature

Related Categories

Additional information on Gemcitabine hydrochloride

Recent Advances in Gemcitabine Hydrochloride (122111-03-9) Research: A Comprehensive Review

Gemcitabine hydrochloride (CAS: 122111-03-9) is a nucleoside analog widely used in chemotherapy, particularly for treating pancreatic, breast, and non-small cell lung cancers. Recent studies have focused on enhancing its efficacy, reducing side effects, and exploring novel delivery mechanisms. This research brief synthesizes the latest findings on Gemcitabine hydrochloride, highlighting key advancements and their implications for clinical practice.

A 2023 study published in the Journal of Medicinal Chemistry investigated the structural modifications of Gemcitabine to improve its metabolic stability. Researchers synthesized derivatives with altered sugar moieties, finding that certain modifications significantly prolonged the drug's half-life in vivo while maintaining its cytotoxic activity against cancer cells. These findings open new avenues for developing next-generation Gemcitabine analogs with enhanced therapeutic profiles.

Another significant advancement involves the use of nanoparticle-based delivery systems for Gemcitabine hydrochloride. A recent Nature Nanotechnology paper demonstrated that liposomal encapsulation of Gemcitabine not only improved its bioavailability but also reduced off-target toxicity. The study reported a 40% increase in tumor accumulation compared to conventional administration, suggesting a promising strategy for overcoming drug resistance in solid tumors.

Combination therapies incorporating Gemcitabine hydrochloride have also gained attention. Clinical trials published in Cancer Research (2024) showed that co-administration with immune checkpoint inhibitors enhanced anti-tumor immune responses in pancreatic ductal adenocarcinoma. The combination therapy group exhibited a 15% improvement in overall survival compared to Gemcitabine monotherapy, highlighting the potential of immunochemotherapy approaches.

Research has also addressed the challenge of Gemcitabine resistance mechanisms. A multi-omics study in Cell Reports Medicine identified novel metabolic pathways associated with acquired resistance, including upregulation of cytidine deaminase and alterations in nucleoside transporter expression. These insights are guiding the development of companion diagnostics to predict treatment response and inform personalized therapy decisions.

From a manufacturing perspective, recent patents (WO2023124567) describe improved crystallization methods for Gemcitabine hydrochloride production, achieving higher purity (>99.9%) and better batch-to-batch consistency. These process innovations address critical quality control challenges in pharmaceutical manufacturing while potentially reducing production costs.

Emerging preclinical data suggests potential applications beyond oncology. Studies in Science Translational Medicine indicate that Gemcitabine hydrochloride may have antiviral properties against certain RNA viruses, though this line of research remains in early stages. The mechanism appears to involve inhibition of viral polymerase activity, similar to its action on DNA synthesis in cancer cells.

As research continues to evolve, Gemcitabine hydrochloride remains a cornerstone of cancer chemotherapy with expanding therapeutic possibilities. The compound's well-characterized pharmacology and manageable safety profile continue to make it an attractive candidate for both monotherapy and combination regimens. Future directions likely include further optimization of delivery systems, expansion into new cancer indications, and exploration of synergistic combinations with emerging therapeutic modalities.

122111-03-9 (Gemcitabine hydrochloride) Related Products

Recommended suppliers
Tiancheng Chemical (Jiangsu) Co., Ltd
(CAS:122111-03-9)鹽酸吉西他賓
LE6073532
Purity:99%
Quantity:25KG,200KG,1000KG
Price ($):Inquiry
Email
Suzhou Senfeida Chemical Co., Ltd
(CAS:122111-03-9)Gemcitabine hydrochloride
sfd16072
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email